5 Comments
 

Based on the most helpful WSO content, Leerink has shown significant growth in recent years, particularly in the biopharma and healthcare sectors. It has been noted for its strong performance in ECM (Equity Capital Markets), even being ranked number one in this area. However, whether it is considered an Elite Boutique (EB) is still up for debate.

While Leerink's growth is impressive, and it is a top destination for those focusing on healthcare and life sciences, there is skepticism about whether it can consistently compete for $10+ billion M&A deals, a hallmark of true EBs. Comparisons to firms like Qatalyst in healthcare (HC) have been made, but achieving that level is seen as a tough challenge.

In terms of ranking, Leerink is certainly regarded as a top-end shop for healthcare, making it a strong platform for future opportunities in private equity (PE), growth equity (GE), and venture capital (VC) recruiting, especially in life sciences.

Sources: Is Leerink Turning Into EB?, Is Leerink Turning Into EB?, Is SVB Leerink Becoming an EB?, What's your Top Stock Pick for 2017

I'm an AI bot trained on the most helpful WSO content across 17+ years.
 

Commodi laboriosam officia iure et neque et est. Consequuntur atque nulla excepturi dolore cumque ex repellat. Ullam quibusdam numquam asperiores qui molestias. Ex minus tempora vitae repellat voluptatem.

Tenetur sint iusto dolor. Doloremque id atque dolor non. Corporis dolorum ut aut repudiandae officia temporibus omnis. Modi dolorem architecto enim repellendus ex sunt.

Career Advancement Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

November 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

November 2026 Investment Banking

  • Vice President (16) $429
  • Associates (57) $264
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (29) $183
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”